0 false false false false false false false false false false true false false true true true true No description of principal activity 2024-10-01 Sage Accounts Production Advanced 2025 - FRS102_2025 251 476 xbrli:pure xbrli:shares iso4217:GBP 15155132 2024-10-01 2025-09-30 15155132 2025-09-30 15155132 2024-09-30 15155132 2023-10-01 2024-09-30 15155132 2024-09-30 15155132 2023-09-30 15155132 bus:RegisteredOffice 2024-10-01 2025-09-30 15155132 bus:Director1 2024-10-01 2025-09-30 15155132 core:ShareCapital 2023-10-01 2024-09-30 15155132 core:RetainedEarningsAccumulatedLosses 2023-10-01 2024-09-30 15155132 core:RetainedEarningsAccumulatedLosses 2024-10-01 2025-09-30 15155132 core:WithinOneYear 2025-09-30 15155132 core:WithinOneYear 2024-09-30 15155132 core:ShareCapital 2025-09-30 15155132 core:ShareCapital 2024-09-30 15155132 core:RetainedEarningsAccumulatedLosses 2025-09-30 15155132 core:RetainedEarningsAccumulatedLosses 2024-09-30 15155132 bus:Director1 2024-09-30 15155132 bus:Director1 2025-09-30 15155132 bus:Director1 2024-09-30 15155132 bus:Director1 2023-10-01 2024-09-30 15155132 bus:SmallEntities 2024-10-01 2025-09-30 15155132 bus:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 15155132 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 15155132 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 15155132 bus:FullAccounts 2024-10-01 2025-09-30
COMPANY REGISTRATION NUMBER: 15155132
BADRANMD LIMITED
Unaudited Financial Statements
30 September 2025
BADRANMD LIMITED
Financial Statements
Year ended 30 September 2025
Contents
Page
Director's report
1
Statement of comprehensive income
2
Statement of financial position
3
Statement of changes in equity
4
Notes to the financial statements
5
BADRANMD LIMITED
Director's Report
Year ended 30 September 2025
The director presents his report and the unaudited financial statements of the company for the year ended 30 September 2025 .
Director
The director who served the company during the year was as follows:
A. Badran
Small company provisions
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on 30 July 2026 and signed on behalf of the board by:
A. Badran
Director
Registered office:
C/O 24 Church Road
Crystal Palace
;ONDON
ENGLAND
SE19 2ET
BADRANMD LIMITED
Statement of Comprehensive Income
Year ended 30 September 2025
2025
2024
Note
£
£
Administrative expenses
251
476
----
----
Operating loss
( 251)
( 476)
----
----
Loss before taxation
( 251)
( 476)
Tax on loss
–
–
----
----
Loss for the financial year and total comprehensive income
( 251)
( 476)
----
----
All the activities of the company are from continuing operations.
The company has no other recognised items of income and expenses other than the results for the year as set out above.
BADRANMD LIMITED
Statement of Financial Position
30 September 2025
2025
2024
Note
£
£
Current assets
Cash at bank and in hand
9
–
Creditors: amounts falling due within one year
4
735
475
----
----
Net current liabilities
726
475
----
----
Total assets less current liabilities
( 726)
( 475)
----
----
Capital and reserves
Called up share capital
1
1
Profit and loss account
( 727)
( 476)
----
----
Shareholder deficit
( 726)
( 475)
----
----
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
For the year ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 30 July 2026 , and are signed on behalf of the board by:
A. Badran
Director
Company registration number: 15155132
BADRANMD LIMITED
Statement of Changes in Equity
Year ended 30 September 2025
Called up share capital
Profit and loss account
Total
£
£
£
At 1 October 2023
–
–
–
Loss for the year
( 476)
( 476)
----
----
----
Total comprehensive income for the year
–
( 476)
( 476)
Issue of shares
1
–
1
----
----
----
Total investments by and distributions to owners
1
–
1
At 30 September 2024
1
( 476)
( 475)
Loss for the year
( 251)
( 251)
----
----
----
Total comprehensive income for the year
–
( 251)
( 251)
----
----
----
At 30 September 2025
1
( 727)
( 726)
----
----
----
BADRANMD LIMITED
Notes to the Financial Statements
Year ended 30 September 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is C/O 24 Church Road, Crystal Palace, ;ONDON, SE19 2ET, ENGLAND.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Creditors: amounts falling due within one year
2025
2024
£
£
Other creditors
735
475
----
----
5. Director's advances, credits and guarantees
During the year the director entered into the following advances and credits with the company:
2025
Balance brought forward
Advances/ (credits) to the director
Balance outstanding
£
£
£
A. Badran
( 475)
( 260)
( 735)
----
----
----
2024
Balance brought forward
Advances/ (credits) to the director
Balance outstanding
£
£
£
A. Badran
–
( 475)
( 475)
----
----
----